Reading view
Behavior Quotient Learning for Low-Rank Adaptation of LLM Agents
CityPlanner: A Sandbox Agent for Executable Urban Planning
KernelGenBench: Can LLMs and Agents Write Efficient Kernels Across Operator Sources and Hardware Platforms?
Author Correction: A mouse brain stereotaxic topographic atlas with isotropic 1-μm resolution
Nature, Published online: 07 September 2026; doi:10.1038/s41586-026-11094-2
Author Correction: A mouse brain stereotaxic topographic atlas with isotropic 1-μm resolutionThe RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulation
Oncogene, Published online: 03 September 2026; doi:10.1038/s41388-026-03959-7
The RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulationATIC Promotes LIHC Progression and Serves as an Independent Prognostic Marker: A Pan-cancer Transcriptomic Analysis
Curr Mol Med. 2026 May 11. doi: 10.2174/0115665240438824260113042223. Online ahead of print.
ABSTRACT
BACKGROUND: 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/ IMP cyclohydrolase(ATIC) is a 64-kDa bifunctional enzyme, 5-aminoimidazole- 4-carboxamide ribonucleotide formyltransferase (AICART) and IMP cyclohydrolase, respectively. catalyzes the last two steps of the purine ab initio biosynthetic pathway. ATIC has been implicated in cancer progression, but its pan-cancer profile and specific prognostic utility in liver hepatocellular carcinoma (LIHC) remain incompletely defined.
METHODS: We analyzed TCGA RNA-seq data across 33 tumor types to assess ATIC expression, diagnostic performance (ROC/AUC), and prognostic associations (OS, DSS, PFI). We correlated ATIC expression with immune infiltration, TMB, MSI, and predicted neoantigen load, and constructed a LIHC-specific prognostic nomogram integrating ATIC and clinicopathologic features. Enrichment analyses (STRING, GO/KEGG, GSEA) and pharmacogenomic correlations (GDSC, CTRP) were performed to explore mechanisms and drug sensitivities.
RESULTS: ATIC was significantly upregulated in 16 tumor types, including LIHC (p<0.001). Pan-cancer ROC analyses showed high diagnostic accuracy in several cancers (examples: CHOL AUC=1.000, LIHC AUC=0.936, LUAD AUC=0.947). High ATIC expression associated with poorer OS in ACC, HNSC, LIHC, and PAAD (eg, LIHC: HR=1.39(1.04-1.85), p=0.028). In LIHC, ATIC correlated with advanced T stage, higher grade, elevated AFP, and shorter OS. Multivariable Cox regression identified ATIC expression and pathological T stage as independent predictors; time-dependent ROC for the LIHC nomogram showed AUCs of 0.711, 0.649, and 0.653 at 1, 3, and 5 years, respectively. GSEA indicated enrichment of PI3K-AKT-mTOR, MYC targets, and cell-cycle pathways in ATIC-high LIHC. High ATIC expression correlated with predicted increased sensitivity to sorafenib, doxorubicin, cisplatin, epothilone, and mitomycin in the TCGA-LIHC cohort.
DISCUSSION: ATIC upregulation across cancers links to tumor progression, immune modulation, and prognosis (LIHC), suggesting oncogenic roles in pan-cancer contexts. TCGA multi-omics show ATIC associates with immune/molecular subtypes, MSI/TMB/neoantigens, and predicts drug sensitivity, indicating diagnostic/prognostic potential.
CONCLUSION: ATIC is broadly upregulated across cancers and functions as an independent prognostic biomarker in LIHC. The ATIC-integrated nomogram shows modest predictive accuracy for LIHC survival. Our results implicate ATIC in oncogenic signaling (PI3K-AKT-mTOR, MYC, and cell-cycle) and suggest ATIC as a candidate biomarker to guide targeted and chemotherapeutic strategies in LIHC. Further in vitro and in vivo validation is warranted.
PMID:42152649 | DOI:10.2174/0115665240438824260113042223
Imaging interface-controlled bulk oxygen spillover
Nature, Published online: 15 April 2026; doi:10.1038/s41586-026-10324-x
In situ microscopic single-particle imaging demonstrates the significance of rationally engineered metal–support interfaces for activating the oxygen in bulk catalyst, helping elucidate reaction pathways in catalytic conversions.Document Parsing Unveiled: Techniques, Challenges, and Prospects for Structured Information Extraction
Infeasibility Aware Large Language Models for Combinatorial Optimization
ContextBudget: Budget-Aware Context Management for Long-Horizon Search Agents
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4
Oncogene, Published online: 01 April 2026; doi:10.1038/s41388-026-03752-6
STAT3-mediated transactivation of NOVA2 promotes lung adenocarcinoma metastasis by splicing SMAD4Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)
J Thorac Oncol. 2026 Mar 26:103696. doi: 10.1016/j.jtho.2026.103696. Online ahead of print.
ABSTRACT
INTRODUCTION: Minimal residual disease (MRD) detection using liquid biopsy is an emerging tool for risk stratification and monitoring for recurrence in resected early-stage NSCLC. There is increasing need for clear guidance on its optimal clinical implementation.
METHODS: The Asian Thoracic Oncology Research Group (ATORG) convened a multi-disciplinary panel of 27 experts to develop a consensus statement on the clinical application of ctDNA-based MRD testing in early-stage resected NSCLC, using a structured Delphi methodology. Statements were organized into broad thematic domains: Assay validity and standardization; Harmonization in research and trials; Clinical application; Challenges in implementation; Consensus recommendations; Infrastructure for regional MRD adoption; and Roadmap for pragmatic trials.
RESULTS: A total of 23 position statements were developed, of which all except one achieved strong consensus. The consensus highlighted the need to define minimum analytical performance thresholds for MRD assays, improve standardization of reporting metrics, and clear guidelines for pre-analytical handling. Harmonization of blood sampling timepoints and terminology across clinical trials is also essential to confirm the prognostic value of MRD assays. While current MRD assays demonstrate high specificity and positive predictive value, variable sensitivity precludes routine use for adjuvant therapy de-escalation outside clinical trials. Broader access, sustainable funding, ongoing consensus building and collaborative real-world data generation are also critical to support clinical implementation and adoption. Future clinical trials must account for the distinct biology and changing standards of care associated with different driver genes.
CONCLUSION: These consensus recommendations provide a pragmatic framework to guide the responsible integration of MRD testing into clinical research and practice.
PMID:41903701 | DOI:10.1016/j.jtho.2026.103696